Reevaluation and update on efficacy and safety of neostigmine for reversal of neuromuscular blockade

Jie Luo, Shuting Chen, Su Min, Lihua Peng, Jie Luo, Shuting Chen, Su Min, Lihua Peng

Abstract

Postoperative residual neuromuscular block is a serious threat which endangers the patient safety. Neostigmine has been the most commonly used anticholinesterase for the pharmacological reversal of neuromuscular blockade. Although newer agents have been introduced recently, neostigmine has some irreplaceable advantages, including broad-spectrum reversal of all nondepolarizing neuromuscular blocking drugs, low cost, and availability of more related data for clinical practice to refer to. Neostigmine is also noticed to have some drawbacks, such as the inability to reverse profound and deep blockade, potential induction of muscle weakness, cardiovascular adverse effects, and so on. Data on the usage of neostigmine in the geriatric and the pediatric population are still insufficient. Some discrepancies are observed in the results from previous studies which need further investigation. However, recent studies offer some renewed information. Regarding both efficacy and safety, the key for successful reversal of neuromuscular blockade is to use neostigmine "appropriately," optimizing the dosage and timing of administration under close monitoring.

Keywords: anticholin-esterase; neuromuscular reversal; postanesthesia care; postoperative complication; postoperative residual neuromuscular block.

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

References

    1. Meara JG, Leather AJ, Hagander L, et al. Global Surgery 2030: evidence and solutions for achieving health, welfare, and economic development. Lancet. 2015;386(9993):569–624.
    1. Murphy GS, Szokol JW, Avram MJ, et al. Neostigmine administration after spontaneous recovery to a train-of-four ratio of 0.9 to 1.0: a randomized controlled trial of the effect on neuromuscular and clinical recovery. Anesthesiology. 2018;128(1):27–37.
    1. Debaene B, Plaud B, Dilly MP, Donati F. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology. 2003;98(5):1042–1048.
    1. Baillard C, Gehan G, Reboul-Marty J, Larmignat P, Samama CM, Cupa M. Residual curarization in the recovery room after vecuronium. Br J Anaesth. 2000;84(3):394–395.
    1. Brull SJ, Kopman AF. Current status of neuromuscular reversal and monitoring: challenges and opportunities. Anesthesiology. 2017;126(1):173–190.
    1. Arbous MS, Meursing AE, van Kleef JW, et al. Impact of anesthesia management characteristics on severe morbidity and mortality. Anesthesiology. 2005;102(2):257–268.
    1. Bulka CM, Terekhov MA, Martin BJ, Dmochowski RR, Hayes RM, Ehrenfeld JM. Nondepolarizing neuromuscular blocking agents, reversal, and risk of postoperative pneumonia. Anesthesiology. 2016;125(4):647–655.
    1. Murphy GS, De Boer HD, Eriksson LI, Miller RD. Reversal (antagonism) of neuromuscular blockade. In: Miller RD, Cohen NH, Eriksson LI, Fleisher LA, Wiener-Kronish JP, Young WL, editors. Miller’s Anesthesia. 8th ed. Philadelphia: Elsevier; 2015. pp. 995–1027.
    1. Vymazal T, Krecmerova M, Bicek V, Lischke R. Feasibility of full and rapid neuromuscular blockade recovery with sugammadex in myasthenia gravis patients undergoing surgery – a series of 117 cases. Ther Clin Risk Manag. 2015;11:1593–1596.
    1. Montague J, Halloran C. Reversing non-depolarising muscle relaxants, nausea and residual curarisation. Anaesthesia. 2016;71(4):478.
    1. Paton F, Paulden M, Chambers D, et al. Sugammadex compared with neostigmine/glycopyrrolate for routine reversal of neuromuscular block: a systematic review and economic evaluation. Br J Anaesth. 2010;105(5):558–567.
    1. Cronnelly R, Stanski DR, Miller RD, Sheiner LB, Sohn YJ. Renal function and the pharmacokinetics of neostigmine in anesthetized man. Anesthesiology. 1979;51(3):222–226.
    1. Morris RB, Cronnelly R, Miller RD, Stanski DR, Fahey MR. Pharmacokinetics of edrophonium and neostigmine when antagonizing d-tubocurarine neuromuscular blockade in man. Anesthesiology. 1981;54(5):399–402.
    1. Berkó S, Szűcs KF, Balázs B, et al. Electroporation-delivered transdermal neostigmine in rats: equivalent action to intravenous administration. Drug Des Devel Ther. 2016;10:1695–1701.
    1. Kirkegaard H, Heier T, Caldwell JE. Efficacy of tactile-guided reversal from cisatracurium-induced neuromuscular block. Anesthesiology. 2002;96(1):45–50.
    1. Lien CA. Neostigmine: how much is necessary for patients who receive a nondepolarizing neuromuscular blocking agent? Anesthesiology. 2010;112(1):16–18.
    1. Brull SJ, Murphy GS. Residual neuromuscular block: lessons unlearned. Part II: methods to reduce the risk of residual weakness. Anesth Analg. 2010;111(1):129–140.
    1. Maybauer DM, Geldner G, Blobner M, et al. Incidence and duration of residual paralysis at the end of surgery after multiple administrations of cisatracurium and rocuronium. Anaesthesia. 2007;62(1):12–17.
    1. Pietraszewski P, Gaszyński T. Residual neuromuscular block in elderly patients after surgical procedures under general anaesthesia with rocuronium. Anaesthesiol Intensive Ther. 2013;45(2):77–81.
    1. Kopman AF, Eikermann M. Antagonism of non-depolarising neuromuscular block: current practice. Anaesthesia. 2009;64(Suppl 1):22–30.
    1. Miller RD, Ward TA. Monitoring and pharmacologic reversal of a nondepolarizing neuromuscular blockade should be routine. Anesth Analg. 2010;111(1):3–5.
    1. Naguib M, Kopman AF, Lien CA, Hunter JM, Lopez A, Brull SJ. A survey of current management of neuromuscular block in the United States and Europe. Anesth Analg. 2010;111(1):110–119.
    1. Payne JP, Hughes R, Al Azawi S. Neuromuscular blockade by neostigmine in anaesthetized man. Br J Anaesth. 1980;52(1):69–76.
    1. Goldhill DR, Wainwright AP, Stuart CS, Flynn PJ. Neostigmine after spontaneous recovery from neuromuscular blockade. Effect on depth of blockade monitored with train-of-four and tetanic stimuli. Anaesthesia. 1989;44(4):293–299.
    1. Meyer MJ, Bateman BT, Kurth T, Eikermann M. Neostigmine reversal doesn’t improve postoperative respiratory safety. BMJ. 2013;346:f1460.
    1. Grosse-Sundrup M, Henneman JP, Sandberg WS, et al. Intermediate acting non-depolarizing neuromuscular blocking agents and risk of postoperative respiratory complications: prospective propensity score matched cohort study. BMJ. 2012;345:e6329.
    1. Sasaki N, Meyer MJ, Malviya SA, et al. Effects of neostigmine reversal of nondepolarizing neuromuscular blocking agents on postoperative respiratory outcomes: a prospective study. Anesthesiology. 2014;121(5):959–968.
    1. Fortier LP, McKeen D, Turner K, et al. The RECITE study: a Canadian prospective, multicenter study of the incidence and severity of residual neuromuscular blockade. Anesth Analg. 2015;121(2):366–372.
    1. Bronsert MR, Henderson WG, Monk TG, et al. Intermediate-acting nondepolarizing neuromuscular blocking agents and risk of postoperative 30-day morbidity and mortality, and long-term survival. Anesth Analg. 2017;124(5):1476–1483.
    1. Choi ES, Oh AY, Seo KS, et al. Optimum dose of neostigmine to reverse shallow neuromuscular blockade with rocuronium and cisatracurium. Anaesthesia. 2016;71(4):443–449.
    1. Fuchs-Buder T. Neostigmine: timing and dosing in 2016. Anaesth Crit Care Pain Med. 2016;35(4):245–247.
    1. Fuchs-Buder T, Nemes R, Schmartz D. Residual neuromuscular blockade: management and impact on postoperative pulmonary outcome. Curr Opin Anaesthesiol. 2016;29(6):662–667.
    1. Prescott F, Organe G, Rowbotham S. Tubocurarine chloride as an adjunct to anaesthesia; report on 180 cases. Lancet. 1946;2(6412):80–84.
    1. Gray TC, Wilson F. The development and use of muscle relaxants in the United Kingdom. Anesthesiology. 1959;20(4):519–529.
    1. Viby-Mogensen J, Jørgensen BC, Ording H. Residual curarization in the recovery room. Anesthesiology. 1979;50(6):539–541.
    1. Fuchs-Buder T, Meistelman C, Alla F, Grandjean A, Wuthrich Y, Donati F. Antagonism of low degrees of atracurium-induced neuromuscular blockade: dose–effect relationship for neostigmine. Anesthesiology. 2010;112(1):34–40.
    1. Harper NJ, Wallace M, Hall IA. Optimum dose of neostigmine at two levels of atracurium-induced neuromuscular block. Br J Anaesth. 1994;72(1):82–85.
    1. Hunter JM. Is it always necessary to antagonize residual neuromuscular block? Do children differ from adults? Br J Anaesth. 1996;77(6):707–709.
    1. Kaufhold N, Schaller SJ, Stäuble CG, et al. Sugammadex and neostigmine dose-finding study for reversal of residual neuromuscular block at a train-of-four ratio of 0.2 (SUNDRO20)†. Br J Anaesth. 2016;116(2):233–240.
    1. Magorian TT, Lynam DP, Caldwell JE, Miller RD. Can early administration of neostigmine, in single or repeated doses, alter the course of neuromuscular recovery from a vecuronium-induced neuromuscular blockade? Anesthesiology. 1990;73(3):410–414.
    1. McCourt KC, Mirakhur RK, Kerr CM. Dosage of neostigmine for reversal of rocuronium block from two levels of spontaneous recovery. Anaesthesia. 1999;54(7):651–655.
    1. Lederer W, Reiner T, Khuenl-Brady KS. Neostigmine injected 5 minutes after low-dose rocuronium accelerates the recovery of neuromuscular function. J Clin Anesth. 2010;22(6):420–424.
    1. Jones JE, Parker CJ, Hunter JM. Antagonism of blockade produced by atracurium or vecuronium with low doses of neostigmine. Br J Anaesth. 1988;61(5):560–564.
    1. Schaller SJ, Fink H, Ulm K, Blobner M. Sugammadex and neostigmine dose-finding study for reversal of shallow residual neuromuscular block. Anesthesiology. 2010;113(5):1054–1060.
    1. Fuchs-Buder T, Baumann C, De Guis J, Guerci P, Meistelman C. Low-dose neostigmine to antagonise shallow atracurium neuromuscular block during inhalational anaesthesia: a randomised controlled trial. Eur J Anaesthesiol. 2013;30(10):594–598.
    1. Eikermann M, Houle TT. Antagonism of neuromuscular block: all things are poison; only the dose makes a thing not a poison. Br J Anaesth. 2016;116(2):157–159.
    1. McLean DJ, Diaz-Gil D, Farhan HN, Ladha KS, Kurth T, Eikermann M. Dose-dependent association between intermediate-acting neuromuscular-blocking agents and postoperative respiratory complications. Anesthesiology. 2015;122(6):1201–1213.
    1. Eikermann M, Fassbender P, Malhotra A, et al. Unwarranted administration of acetylcholinesterase inhibitors can impair genioglossus and diaphragm muscle function. Anesthesiology. 2007;107(4):621–629.
    1. Kim KS, Cheong MA, Lee HJ, Lee JM. Tactile assessment for the reversibility of rocuronium-induced neuromuscular blockade during propofol or sevoflurane anesthesia. Anesth Analg. 2004;99(4):1080–1085.
    1. Brull SJ, Naguib M. How to catch unicorns (and other fairytales) Anesthesiology. 2018;128(1):1–3.
    1. Astley BA, Katz RL, Payne JP. Electrical and mechanical responses after neuromuscular blockade with vecuronium, and subsequent antagonism with neostigmine or edrophonium. Br J Anaesth. 1987;59(8):983–988.
    1. Caldwell JE. Reversal of residual neuromuscular block with neostigmine at one to four hours after a single intubating dose of vecuronium. Anesth Analg. 1995;80(6):1168–1174.
    1. Eikermann M, Zaremba S, Malhotra A, Jordan AS, Rosow C, Chamberlin NL. Neostigmine but not sugammadex impairs upper airway dilator muscle activity and breathing. Br J Anaesth. 2008;101(3):344–349.
    1. Herbstreit F, Zigrahn D, Ochterbeck C, Peters J, Eikermann M. Neostigmine/glycopyrrolate administered after recovery from neuromuscular block increases upper airway collapsibility by decreasing genioglossus muscle activity in response to negative pharyngeal pressure. Anesthesiology. 2010;113(6):1280–1288.
    1. Caldwell JE. Clinical limitations of acetylcholinesterase antagonists. J Crit Care. 2009;24(1):21–28.
    1. Kirkegaard-Nielsen H, Helbo-Hansen HS, Lindholm P, Severinsen IK, Pedersen HS, Jensen EW. Optimum time for neostigmine reversal of atracurium-induced neuromuscular blockade. Can J Anaesth. 1996;43(9):932–938.
    1. Engbaek J, Ostergaard D, Skovgaard LT, Viby-Mogensen J. Reversal of intense neuromuscular blockade following infusion of atracurium. Anesthesiology. 1990;72(5):803–806.
    1. Jones RK, Caldwell JE, Brull SJ, Soto RG. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology. 2008;109(5):816–824.
    1. Lemmens HJ, El-Orbany MI, Berry J, Morte JB, Jr, Martin G. Reversal of profound vecuronium-induced neuromuscular block under sevoflurane anesthesia: sugammadex versus neostigmine. BMC Anesthesiol. 2010;10(15):15.
    1. Caldwell JE, Robertson EN, Baird WL. Antagonism of profound neuromuscular blockade induced by vecuronium or atracurium. Comparison of neostigmine with edrophonium. Br J Anaesth. 1986;58(11):1285–1289.
    1. Plaud B, Debaene B, Donati F, Marty J. Residual paralysis after emergence from anesthesia. Anesthesiology. 2010;112(4):1013–1022.
    1. Tajaate N, Schreiber JU, Fuchs-Buder T, Jelting Y, Kranke P. Neostigmine-based reversal of intermediate acting neuromuscular blocking agents to prevent postoperative residual paralysis: A systematic review. Eur J Anaesthesiol. 2018;35(3):184–192.
    1. Dubovoy T, Housey M, Devine S, Kheterpal S. Observational study on patterns of neuromuscular blockade reversal. BMC Anesthesiol. 2016;16(1):103.
    1. Hristovska AM, Duch P, Allingstrup M, Afshari A. Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults. Cochrane Database Syst Rev. 2017;8:CD012763.
    1. Song IA, Seo KS, Oh AY, et al. Timing of reversal with respect to three nerve stimulator end-points from cisatracurium-induced neuromuscular block. Anaesthesia. 2015;70(7):797–802.
    1. Fox MA, Keens SJ, Utting JE. Neostigmine in the antagonism of the action of atracurium. Br J Anaesth. 1987;59(4):468–472.
    1. Ostheimer GW. A comparison of glycopyrrolate and atropine during reversal of nondepolarizing neuromuscular block with neostigmine. Anesth Analg. 1977;56(2):182–186.
    1. Tramèr MR, Fuchs-Buder T. Omitting antagonism of neuromuscular block: effect on postoperative nausea and vomiting and risk of residual paralysis. A systematic review. Br J Anaesth. 1999;82(3):379–386.
    1. Abad-Gurumeta A, Ripollés-Melchor J, Casans-Francés R, et al. A systematic review of sugammadex vs neostigmine for reversal of neuromuscular blockade. Anaesthesia. 2015;70(12):1441–1452.
    1. Cheng CR, Sessler DI, Apfel CC. Does neostigmine administration produce a clinically important increase in postoperative nausea and vomiting? Anesth Analg. 2005;101(5):1349–1355.
    1. Murphy GS, Szokol JW, Avram MJ, et al. Residual neuromuscular block in the elderly: incidence and clinical implications. Anesthesiology. 2015;123(6):1322–1336.
    1. Young WL, Matteo RS, Ornstein E. Duration of action of neostigmine and pyridostigmine in the elderly. Anesth Analg. 1988;67(8):775–778.
    1. Cope TM, Hunter JM. Selecting neuromuscular-blocking drugs for elderly patients. Drugs Aging. 2003;20(2):125–140.
    1. Marsh RH, Chmielewski AT, Goat VA. Recovery from pancuronium. A comparison between old and young patients. Anaesthesia. 1980;35(12):1193–1196.
    1. Young WL, Backus W, Matteo RS, Ornstein E, Diaz J. Pharmacokinetics and pharmacodynamics of neostigmine in the elderly [abstract] Anesthesiology. 1984;61(3A):A300.
    1. Chmielewski AT, Loach AB, Goat VA. Recovery from neuromuscular blockade. A comparison between old and young patients. Anaesthesia. 1978;33(6):539–542.
    1. Koscielniak-Nielsen ZJ, Law-Min JC, Donati F, Bevan DR, Clement P, Wise R. Dose-response relations of doxacurium and its reversal with neostigmine in young adults and healthy elderly patients. Anesth Analg. 1992;74(6):845–850.
    1. McCarthy GJ, Cooper R, Stanley JC, Mirakhur RK. Dose-response relationships for neostigmine antagonism of vecuronium-induced neuromuscular block in adults and the elderly. Br J Anaesth. 1992;69(3):281–283.
    1. Muravchick S, Owens WD, Felts JA. Glycopyrrolate and cardiac dysrhythmias in geriatric patients after reversal of neuromuscular blockade. Can Anaesth Soc J. 1979;26(1):22–25.
    1. Owens WD, Waldbaum LS, Stephen CR. Cardiac dysrhythmia following reversal of neuromuscular blocking agents in geriatric patients. Anesth Analg. 1978;57(2):186–190.
    1. Mirakhur RK. Antagonism of neuromuscular block in the elderly. A comparison of atropine and glycopyrronium in a mixture with neostigmine. Anaesthesia. 1985;40(3):254–258.
    1. Ledowski T, O’Dea B, Meyerkort L, Hegarty M, Von Ungern-Sternberg BS. Postoperative residual neuromuscular paralysis at an Australian tertiary children’s hospital. Anesthesiol Res Pract. 2015;2015:410248.
    1. Cook DR. Muscle relaxants in infants and children. Anesth Analg. 1981;60(5):335–343.
    1. Bush GH, Stead AL. The use of d-tubocurarine in neonatal anaesthesia. Br J Anaesth. 1962;34:721–728.
    1. Fisher DM, Cronnelly R, Miller RD, Sharma M. The neuromuscular pharmacology of neostigmine in infants and children. Anesthesiology. 1983;59(3):220–225.
    1. Bevan JC, Purday JP, Reimer EJ, Bevan DR. Reversal of doxacurium and pancuronium neuromuscular blockade with neostigmine in children. Can J Anaesth. 1994;41(11):1074–1080.
    1. Abdulatif M, Mowafi H, Al-Ghamdi A, El-Sanabary M. Dose-response relationships for neostigmine antagonism of rocuronium-induced neuromuscular block in children and adults. Br J Anaesth. 1996;77(6):710–715.
    1. Meakin G, Sweet PT, Bevan JC, Bevan DR. Neostigmine and edrophonium as antagonists of pancuronium in infants and children. Anesthesiology. 1983;59(4):316–321.
    1. Gwinnutt CL, Walker RW, Meakin G. Antagonism of intense atracurium-induced neuromuscular block in children. Br J Anaesth. 1991;67(1):13–16.
    1. Black GW, Mirakhur RK, Keilty SR, Love SH. Reversal of non-depolarising neuromuscular block in children: a comparison of atropine and glycopyrrolate in a mixture with neostigmine. Anaesthesia. 1980;35(9):913–916.
    1. Debaene B, Meistelman C, D’Hollander A. Recovery from vecuronium neuromuscular blockade following neostigmine administration in infants, children, and adults during halothane anesthesia. Anesthesiology. 1989;71(6):840–844.
    1. Motsch J, Leuwer M, Böttiger BW, Bach A, Schönstedt R, Martin E. Dose-response, time-course of action and recovery of rocuronium bromide in children during halothane anaesthesia. Eur J Anaesthesiol Suppl. 1995;11:73–78.
    1. Liu J, Cheng Z. Comparison of neostigmine induced reversal of rocuronium in different age children. Zhonghua Yi Xue Za Zhi. 2016;96(10):807–811.
    1. Fisher DM, Cronnelly R, Sharma M, Miller RD. Clinical pharmacology of edrophonium in infants and children. Anesthesiology. 1984;61(4):428–433.
    1. Cook DR. Paediatric anaesthesia: pharmacological considerations. Drugs. 1976;12(3):212–221.
    1. Yang L, Yang D, Li Q, Zuo Y, Lu D. Neostigmine for reversal of neuromuscular block in paediatric patients. Cochrane Database Syst Rev. 2014;5(5):CD010110.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj